Sign Out
History of severe and unexpected reactions to fluoropyrimidine therapy.
Hypersensitivity to Capecitabine or to any of the excipients.
In patients with known complete absence of dihydropyrimidine dehydrogenase (DPD) activity.
During pregnancy and lactation.
In patients with severe leukopenia, neutropenia, or thrombocytopenia.
In patients with severe hepatic impairment. In patients with severe renal impairment (creatinine clearance below 30 mL/min).
Treatment with sorivudine or its chemically related analogues, such as brivudine.
If contraindications exist to any of the medicinal products in the combination regimen, that medicinal product should not be used.
Continue with Google